<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04443400</url>
  </required_header>
  <id_info>
    <org_study_id>PekingUTN</org_study_id>
    <nct_id>NCT04443400</nct_id>
  </id_info>
  <brief_title>Early Detection of Cardiac Damage by Two-Dimensional Speckle Tracking Echocardiography After Thoracic Radiation Therapy</brief_title>
  <official_title>Early Detection of Cardiac Damage by Two-Dimensional Speckle Tracking Echocardiography After Thoracic Radiation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to detecte and predict early subclinical cardiac damage induced&#xD;
      by thoracic radiation therapy based on two-dimensional speckle tracking echocardiography&#xD;
      combined with multiple circulating biomarkers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a monocentric prospective cohort study in which 100 patients treated for malignant&#xD;
      tumors and with cardiac radiation exposure will be included.All patient will be followed for&#xD;
      12 months after radiotherapy. Echocardiography, 2D STE parameters and circulating biomarkers&#xD;
      will be collected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Early Detection of Cardiac Damage by Two-Dimensional Speckle Tracking Echocardiography After Thoracic Radiation Therapy</measure>
    <time_frame>2020-2021</time_frame>
    <description>To detecte early subclinical cardiac damage induced by thoracic radiation therapy, based on two-dimensional speckle tracking echocardiography combined with multiple circulating biomarkers</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Radiation Therapy</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples will be collected&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients with thoracic radiotherapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  with malignant tumors&#xD;
&#xD;
          -  will receive radiotherapy&#xD;
&#xD;
          -  with cardiac exposure during the radiotherapy process&#xD;
&#xD;
          -  could receive regular follow-up for 12 months&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  satisfactory echocardiographic images could not be obtained&#xD;
&#xD;
          -  moderate or severe valvular disease&#xD;
&#xD;
          -  cardiomyopathy&#xD;
&#xD;
          -  congenital heart disease&#xD;
&#xD;
          -  refractory hypertension&#xD;
&#xD;
          -  coronary artery disease*&#xD;
&#xD;
          -  heart failure&#xD;
&#xD;
          -  arrhythmia requiring intervention&#xD;
&#xD;
          -  pericarditis&#xD;
&#xD;
          -  acute myocarditis&#xD;
&#xD;
          -  participating in other clinical studies of drug intervention&#xD;
&#xD;
          -  severe liver and kidney dysfunction&#xD;
&#xD;
          -  autoimmune disease&#xD;
&#xD;
          -  pulmonary hypertension&#xD;
&#xD;
        coronary artery disease: at least 50% stenosis besed on previous coronary angiography or&#xD;
        CTA, or with a history of percutaneous coronary stent implantation.&#xD;
&#xD;
        *: with LVEF&lt;50%, unstable anginaï¼Œor acute myocardial infarction within 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Zhu</last_name>
    <role>Study Director</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dan Zhu, M.D.</last_name>
    <phone>+8613810103532</phone>
    <phone_ext>+8613810103532</phone_ext>
    <email>andrea_zhu@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tingcui Li</last_name>
    <phone>+8618801236290</phone>
    <phone_ext>+8618801236290</phone_ext>
    <email>tingcui2019@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Zhu</last_name>
      <phone>+8613810103532</phone>
      <phone_ext>+8613810103532</phone_ext>
      <email>andrea_zhu@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Tingcui Li</last_name>
      <phone>+8618801236290</phone>
      <phone_ext>+8618801236290</phone_ext>
      <email>tingcui2019@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 21, 2020</study_first_submitted>
  <study_first_submitted_qc>June 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2020</study_first_posted>
  <last_update_submitted>June 21, 2020</last_update_submitted>
  <last_update_submitted_qc>June 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

